The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from CNW Group

TSO3 Files New and Simplified Submission to the US Regulatory Agency

Monday, January 28, 2013

TSO3 Files New and Simplified Submission to the US Regulatory Agency06:00 EST Monday, January 28, 2013Company seeking United States clearance for its STERIZONE® 125L+ SterilizerTicker:  TSX - TOS     Shares Outstanding: 65,888,182QUEBEC CITY, Jan. 28, 2013 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that consistent with its December 14 2012 disclosure, the Company has filed a new and simplified submission with the US regulatory agency seeking commercial clearance of its STERIZONE® 125L+ Sterilizer in that market.The simplified submission presents a single cycle sterilizer offering improved claims. The Agency had acknowledged this new approach by TSO3, after reviewing answers to questions raised from the previous submission and asked the Company to re-file a new, cleaned up and simplified submission."Obtaining US regulatory clearance remains our top priority", stated R.M. (Ric) Rumble, CEO of TSO3. "We believe the submission is complete and the use of a single cycle with expanded claims increases our confidence in making tangible progress towards US regulatory clearance".The submission by TSO3 will first undergo an "acceptance review" to ensure that the file is administratively complete as per the Agency's requirements. According to the most recently updated US regulatory guidelines, the Agency should provide such assessment within 15 calendar days. If the file is accepted, the Agency will grant a file number and will initiate the "substantive review" process. Complete US regulatory guidelines for 510(k) clearances can be found at:http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089735.htmAbout TSO3TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential.  TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.For more information about TSO3, visit the Company's Web site at www.tso3.comThe statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.SOURCE: TSO3 INC.For further information: Caroline Côté Director - Investor and Business Relations (418) 651-0003, Ext. 237 Email: ccote@tso3.com